Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

This should be front-page news EVERYWHERE. The LARGEST real-world study of ivermectin + mebendazole in cancer patients found that nearly HALF declared CANCER DISAPPEARANCE or TUMOR SHRINKAGE after just 6 months. 84.4% experienced clinical benefit. This was not surprising, as HUNDREDS of preclinical studies have shown anti-parasitics attack tumors... show more

Nicolas Hulscher, MPH

257,665 subscribers

19,219 views • 4 months ago •via X (Twitter)

Health & Wellness News & Politics Science & Technology

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

84.4% of cancer patients taking ivermectin + mebendazole declared NO EVIDENCE OF DISEASE, TUMOR SHRINKAGE, or CANCER STABILIZATION after 6 months. HUNDREDS of preclinical studies explain why: anti-parasitics exert over 12 anti-cancer mechanisms across more than 12 cancer types.

84.4% of cancer patients taking ivermectin + mebendazole declared NO EVIDENCE OF DISEASE, TUMOR SHRINKAGE, or CANCER STABILIZATION after 6 months. HUNDREDS of preclinical studies explain why: anti-parasitics exert over 12 anti-cancer mechanisms across more than 12 cancer types.

Nicolas Hulscher, MPH

1,052,068 views • 3 months ago

We are about to publish the LARGEST human ivermectin-cancer study ever conducted. After 6 months, many patients reported their cancer was GONE. HUNDREDS of preclinical studies have shown anti-parasitics attack tumors via 12 distinct mechanisms across more than 12 cancer types.

We are about to publish the LARGEST human ivermectin-cancer study ever conducted. After 6 months, many patients reported their cancer was GONE. HUNDREDS of preclinical studies have shown anti-parasitics attack tumors via 12 distinct mechanisms across more than 12 cancer types.

Nicolas Hulscher, MPH

1,691,840 views • 4 months ago

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 6 months, 84.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY.

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 6 months, 84.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY.

Nicolas Hulscher, MPH

100,530 views • 4 months ago

The single LARGEST human study of ivermectin and mebendazole in cancer patients found that the VAST MAJORITY (84.4%) declared CANCER DISAPPEARANCE, TUMOR SHRINKAGE, or CANCER STABILIZATION.

The single LARGEST human study of ivermectin and mebendazole in cancer patients found that the VAST MAJORITY (84.4%) declared CANCER DISAPPEARANCE, TUMOR SHRINKAGE, or CANCER STABILIZATION.

Nicolas Hulscher, MPH

437,418 views • 3 months ago

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.

Joe Tippens

56,068 views • 4 months ago

We found 84.4% of cancer patients taking ivermectin and mebendazole for 6 months declared either COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH. It’s no surprise the CIA BURIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer growth.

We found 84.4% of cancer patients taking ivermectin and mebendazole for 6 months declared either COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED TUMOR GROWTH. It’s no surprise the CIA BURIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer growth.

Nicolas Hulscher, MPH

175,408 views • 2 months ago

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 4 months, 95.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY. Follow Dr. Zakaria MD. (Dr. Zakaria MD ).

Cancer reportedly DISAPPEARED or REGRESSED in nearly HALF of patients using ivermectin + mebendazole in the LARGEST real-world study to date. After just 4 months, 95.4% of cancer patients reported CLINICAL BENEFIT with these anti-parasitics. Clinical trials are now NECESSARY. Follow Dr. Zakaria MD. (Dr. Zakaria MD ).

Joe Tippens

30,145 views • 4 months ago

🚨COMPLETE REMISSIONS of Stage IV cancers using anti-parasitics are now being documented in the peer-reviewed literature. HUNDREDS of studies find ivermectin and fenbendazole exert over 12 distinct anti-cancer mechanisms across more than 12 cancer types.

🚨COMPLETE REMISSIONS of Stage IV cancers using anti-parasitics are now being documented in the peer-reviewed literature. HUNDREDS of studies find ivermectin and fenbendazole exert over 12 distinct anti-cancer mechanisms across more than 12 cancer types.

Nicolas Hulscher, MPH

5,203,743 views • 4 months ago

HUNDREDS of studies show ivermectin exerts over 12 distinct anti-cancer mechanisms across more than 12 cancer types. That's why COMPLETE REMISSIONS of Stage IV cancers using anti-parasitics are now being published in the peer-reviewed literature. It's also SAFER than Tylenol.

HUNDREDS of studies show ivermectin exerts over 12 distinct anti-cancer mechanisms across more than 12 cancer types. That's why COMPLETE REMISSIONS of Stage IV cancers using anti-parasitics are now being published in the peer-reviewed literature. It's also SAFER than Tylenol.

Joe Tippens

15,391 views • 1 month ago

We found 84% of cancer patients taking ivermectin and mebendazole declared their cancer was either COMPLETELY GONE, SHRUNK, or STOPPED SPREADING after 6 months. This explains why the CIA CLASSIFIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer.

We found 84% of cancer patients taking ivermectin and mebendazole declared their cancer was either COMPLETELY GONE, SHRUNK, or STOPPED SPREADING after 6 months. This explains why the CIA CLASSIFIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer.

Nicolas Hulscher, MPH

75,566 views • 3 months ago

HUNDREDS of studies show ivermectin exerts over 12 distinct anti-cancer mechanisms across more than 12 cancer types. That's why COMPLETE REMISSIONS of Stage IV cancers using anti-parasitics are now being published in the peer-reviewed literature. It's also SAFER than Tylenol.

HUNDREDS of studies show ivermectin exerts over 12 distinct anti-cancer mechanisms across more than 12 cancer types. That's why COMPLETE REMISSIONS of Stage IV cancers using anti-parasitics are now being published in the peer-reviewed literature. It's also SAFER than Tylenol.

Nicolas Hulscher, MPH

138,449 views • 1 month ago

Mel Gibson was NOT lying to Joe Rogan… our peer-reviewed study found 84.4% of cancer patients taking ivermectin + mebendazole declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED CANCER GROWTH. The study just became the #1 RESULT ON GOOGLE. Censorship has FAILED.

Mel Gibson was NOT lying to Joe Rogan… our peer-reviewed study found 84.4% of cancer patients taking ivermectin + mebendazole declared COMPLETE REMISSION, TUMOR SHRINKAGE, or HALTED CANCER GROWTH. The study just became the #1 RESULT ON GOOGLE. Censorship has FAILED.

Nicolas Hulscher, MPH

80,962 views • 2 months ago

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson

Nicolas Hulscher, MPH

763,010 views • 4 months ago

🚨The CIA buried knowledge of the anti-cancer effects of anti-parasitics for over 50 YEARS. We now know that ivermectin exerts over 12 distinct anti-cancer mechanisms across 12 cancer types — while COMPLETE REMISSION of Stage IV cancers using fenbendazole has been documented. This vital line of cancer research was set back more than HALF A CENTURY — and millions of cancer victims have paid the price.

🚨The CIA buried knowledge of the anti-cancer effects of anti-parasitics for over 50 YEARS. We now know that ivermectin exerts over 12 distinct anti-cancer mechanisms across 12 cancer types — while COMPLETE REMISSION of Stage IV cancers using fenbendazole has been documented. This vital line of cancer research was set back more than HALF A CENTURY — and millions of cancer victims have paid the price.

Nicolas Hulscher, MPH

22,556 views • 5 months ago

We found 84% of cancer patients taking ivermectin and mebendazole for 6 months declared their cancer was either COMPLETELY GONE, REGRESSED, or STOPPED SPREADING. It’s no surprise the CIA BURIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer growth.

We found 84% of cancer patients taking ivermectin and mebendazole for 6 months declared their cancer was either COMPLETELY GONE, REGRESSED, or STOPPED SPREADING. It’s no surprise the CIA BURIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer growth.

Nicolas Hulscher, MPH

2,384,907 views • 3 months ago

Ivermectin exerts over TWELVE distinct anti-cancer mechanisms across more than TWELVE cancer types — according to HUNDREDS of studies. And finally, the NIH has officially acknowledged this and launched studies on ivermectin’s ability to eliminate cancer cells.

Ivermectin exerts over TWELVE distinct anti-cancer mechanisms across more than TWELVE cancer types — according to HUNDREDS of studies. And finally, the NIH has officially acknowledged this and launched studies on ivermectin’s ability to eliminate cancer cells.

Nicolas Hulscher, MPH

245,288 views • 6 months ago

The LARGEST systematic review study ever conducted on ivermectin use in cancer patients identified 14 distinct anticancer mechanisms across 12 cancer types and found no safety concerns. Meanwhile, a recent study reported COMPLETE REMISSION of Stage IV cancers with fenbendazole.

The LARGEST systematic review study ever conducted on ivermectin use in cancer patients identified 14 distinct anticancer mechanisms across 12 cancer types and found no safety concerns. Meanwhile, a recent study reported COMPLETE REMISSION of Stage IV cancers with fenbendazole.

Nicolas Hulscher, MPH

90,205 views • 6 months ago

CHEMOTHERAPY: Over $100K a year. Extends survival by a few months… or shortens it. Destroys the body. IVERMECTIN + MEBENDAZOLE: Few grand a year or less. 84.4% clinical benefit in first real-world cancer study. Doesn’t destroy the body. Why is this not front-page news?

CHEMOTHERAPY: Over $100K a year. Extends survival by a few months… or shortens it. Destroys the body. IVERMECTIN + MEBENDAZOLE: Few grand a year or less. 84.4% clinical benefit in first real-world cancer study. Doesn’t destroy the body. Why is this not front-page news?

Nicolas Hulscher, MPH

189,347 views • 3 months ago

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Dr. Zakaria MD

10,766 views • 1 month ago

A Soviet Study Found Ivermectin Had Anti-Cancer Properties. The CIA Classified It. It Wasn't Declassified Until 2011. Soviet scientists discovered that anti-parasitics and tumors share similar mechanisms — and that these compounds showed anti-cancer activity in animals. The CIA buried the study during the Cold War. Decades of potential cancer research lost. Johns Hopkins now holds a patent on mebendazole as an anti-cancer agent. The science was never the problem. The suppression was. Join the Fight: Courtesy of The Absolute Truth The Absolute Truth with Emerald Robinson ✝️, Emerald Robinson Emerald Robinson ✝️ #MedicalFreedom

A Soviet Study Found Ivermectin Had Anti-Cancer Properties. The CIA Classified It. It Wasn't Declassified Until 2011. Soviet scientists discovered that anti-parasitics and tumors share similar mechanisms — and that these compounds showed anti-cancer activity in animals. The CIA buried the study during the Cold War. Decades of potential cancer research lost. Johns Hopkins now holds a patent on mebendazole as an anti-cancer agent. The science was never the problem. The suppression was. Join the Fight: Courtesy of The Absolute Truth The Absolute Truth with Emerald Robinson ✝️, Emerald Robinson Emerald Robinson ✝️ #MedicalFreedom

McCullough Foundation

39,897 views • 3 months ago